<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethanol (topical and injection): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethanol (topical and injection): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethanol (topical and injection): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9342" href="/d/html/9342.html" rel="external">see "Ethanol (topical and injection): Drug information"</a> and <a class="drug drug_patient" data-topicid="118872" href="/d/html/118872.html" rel="external">see "Ethanol (topical and injection): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F131116"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ablysinol;</li>
<li>Epi-Clenz [OTC];</li>
<li>GelRite [OTC];</li>
<li>Lavacol [OTC];</li>
<li>Prevacare [OTC];</li>
<li>ProtecTeaV [OTC] [DSC];</li>
<li>Purell Advanced [OTC];</li>
<li>Purell [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056328"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-infective Agent, Topical</span>;</li>
<li>
<span class="list-set-name">Antidote, Ethylene Glycol Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Methanol Toxicity</span>;</li>
<li>
<span class="list-set-name">Fat Occlusion (Central Venous Catheter), Treatment Agent</span>;</li>
<li>
<span class="list-set-name">Neurolytic</span></li></ul></div>
<div class="block dop drugH1Div" id="F131129"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92f24669-8855-4888-be89-8262b83630ab">Antiseptic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiseptic: </b> Children and Adolescents: Ethyl rubbing alcohol: Topical: Apply 1 to 3 times daily as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ae0dfaf-cbf0-4752-8678-fdb0844e19c6">Methanol or ethylene glycol ingestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methanol or ethylene glycol ingestion:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10497633','lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10497633','lexi-content-ref-12216995'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note:</b> IV administration is the preferred route; continue therapy until ethylene glycol and/or methanol is no longer detected or levels are &lt;20 mg/dL <b>and</b> the patient is asymptomatic <b>and</b> metabolic acidosis has been corrected. If ethylene glycol and/or methanol levels are not available in a timely manner, continue therapy until the estimated time of clearance of ethylene glycol and/or methanol has elapsed <b>and</b> the patient is asymptomatic with a normal pH. If patient has coingested ethanol, measure the baseline serum ethanol concentration and adjust the ethyl alcohol loading dose based on results to achieve a serum ethanol level of ~100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">Absolute ethyl alcohol [98% (196 proof) = 77.4 g EtOH/dL]:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: <b>Note:</b> Consider consultation with a clinical toxicologist or poison control center for options related to compounding IV ethanol.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: 600 to 700 mg/kg [equivalent to 7.6 to 8.9 mL/kg using a 10% solution].</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance (not receiving hemodialysis): Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do <b>not</b> use alcohol regularly</i>: 66 mg/kg/hour (equivalent to 0.83 mL/kg/hour using a <b>10% solution</b>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i> Patients who do use alcohol regularly</i>: 154 mg/kg/hour (equivalent to 1.96 mL/kg/hour using a <b>10% solution</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: <b>Note:</b> Solution must be diluted to a ≤20% concentration with water or juice and administered orally or via a nasogastric tube.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: 600 to 700 mg/kg (equivalent to 0.78 to 0.9 mL/kg using a <b>98% solution</b>).</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance (not receiving hemodialysis): Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do <b>not </b>use alcohol regularly</i>: 66 mg/kg/hour (equivalent to 0.09 mL/kg/hour using a <b>98% solution</b>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do use alcohol regularly</i>: 154 mg/kg/hour (equivalent to 0.20 mL/kg/hour using a <b>98% solution</b>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb297c33-5221-4661-828c-f60ef0f6ddc2">Central venous catheter lock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central venous catheter lock:</b> Limited data available: Infants, Children, and Adolescents: See institution-based protocol: Dehydrated alcohol injection: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Catheter-related blood stream infection (CRBSI):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis:</i>
<b>Note:</b> Use suggested in patients with long term catheters with a history of multiple CRBSI episodes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21460264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21460264'])">Ref</a></span>); dosing regimens variable: 70% ethanol; instill a volume equal to the internal volume of the catheter once daily with a dwell time of 2 to 14 hours; withdraw ethanol at the end of the dwell time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20959638','lexi-content-ref-18558177','lexi-content-ref-21616259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20959638','lexi-content-ref-18558177','lexi-content-ref-21616259'])">Ref</a></span>). Less frequent dosing (3 times per week) for a minimum 4 hour dwell time(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20620333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20620333'])">Ref</a></span>) and once weekly dosing with a 2-hour dwell time(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23232749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23232749'])">Ref</a></span>) have also shown to produce statistically significant reductions in infection rate and catheter loss; most study subjects were receiving long-term outpatient cyclic parenteral nutrition. However, a small case-series observed an increase in infection rate when the frequency of ethanol locks were decreased to less than daily (eg, twice weekly or once weekly; dwell times not specified) during an ethanol shortage; all patients in this study had tunneled silastic catheters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23045557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23045557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> Dosing regimens variable: 70% ethanol; instill a volume equal to the internal volume of the catheter with a dwell time 4 to 25 hours; some protocols utilized single dose and others repeated the dose once daily for 3 to 5 days; dosing should be repeated for each lumen and used in combination with systemic antimicrobials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12902914','lexi-content-ref-21622689','lexi-content-ref-17018464','lexi-content-ref-21499184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12902914','lexi-content-ref-21622689','lexi-content-ref-17018464','lexi-content-ref-21499184'])">Ref</a></span>). For fungal bloodstream infection, case-reports describe success using once daily with dwell times of 2 to 24 hours for 14 days following the patient's first negative blood culture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21844829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21844829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fat occlusion of central venous catheters: Dehydrated alcohol injection: Up to 3 mL of 70% ethanol (maximum: 0.55 mL/kg); instill a volume equal to the internal volume of the catheter; may repeat if patency not restored after 30 to 60 minute dwell time; if dose repeated, reassess after 4-hour dwell time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3116300','lexi-content-ref-8577023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3116300','lexi-content-ref-8577023'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51063790"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. Hemodialysis clearance: 300 to 400 mL/minute with an ethanol removal rate of 280 mg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Methanol or ethylene glycol ingestion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Absolute ethyl alcohol:</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage adjustment for hemodialysis: Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:10em;">IV:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do <b>no</b>t use alcohol regularly</i>: 169 mg/kg/hour (equivalent to 2.13 mL/kg/hour using a <b>10% solution</b>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do use alcohol regularly</i>: 257 mg/kg/hour (equivalent to 3.26 mL/kg/hour using a <b>10% solution</b>).</p>
<p style="text-indent:-2em;margin-left:10em;">Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do <b>not</b> use alcohol regularly</i>: 169 mg/kg/hour (equivalent to 0.22 mL/kg/hour using a <b>98% solution</b>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients who do use alcohol regularly</i>: 257 mg/kg/hour (equivalent to 0.33 mL/kg/hour using a <b>98% solution</b>).</p></div>
<div class="block dohp drugH1Div" id="F51063791"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F131118"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9342" href="/d/html/9342.html" rel="external">see "Ethanol (topical and injection): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92f24669-8855-4888-be89-8262b83630ab">Antiseptic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiseptic:</b>
<i>Liquid denatured alcohol:</i>
<b>Topical:</b> Apply 1 to 3 times daily as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76272e17-2e35-463d-8b1c-e918e551fd73">Therapeutic nerve or ganglion block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Therapeutic nerve or ganglion block: </b>
<i>Dehydrated alcohol injection 98%:</i>
<b>Intraneural:</b> Dosage variable depending upon the site of injection (eg, trigeminal neuralgia: 0.05 to 0.5 mL as a single injection per interspace vs subarachnoid injection: 0.5 to 1 mL as a single injection per interspace); single doses &gt;1.5 mL are seldom required. <b>Note:</b> Administer when pain is from malignant origin only.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16c11061-fa78-4d62-af3b-89fc7d3b5dab">Replenishment of fluid and carbohydrate calories</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Replenishment of fluid and carbohydrate calories:</b>
<i>Dehydrated alcohol infusion:</i> Alcohol 5% and dextrose 5%: 1 to 2 L/day by slow infusion.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b451325-8259-407f-9e01-809531b2e01a">Septal ablation for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septal ablation for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Intracoronary:</b> Dosage variable depending on septal anatomy and rate of contrast wash-out: Single dose: 1 to 3 mL of at least 95% concentration infused slowly into septal arterial branches; maximum dose: 5 mL/procedure. <b>Note:</b> Use the minimum dose necessary to achieve the desired reduction in peak left ventricular outflow tract pressure gradient; smaller amounts may reduce the size of the septal infarct and incidence of complications (eg, complete heart block) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14607462','lexi-content-ref-23076968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14607462','lexi-content-ref-23076968'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ae0dfaf-cbf0-4752-8678-fdb0844e19c6">Methanol or ethylene glycol ingestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methanol or ethylene glycol ingestion (off-label use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10497633','lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10497633','lexi-content-ref-12216995'])">Ref</a></span>):</b>
<b>Note:</b> IV administration is the preferred route; continue therapy until ethylene glycol and/or methanol is no longer detected or levels are &lt;20 mg/dL <b>and</b> the patient is asymptomatic <b>and</b> metabolic acidosis has been corrected. If ethylene glycol and/or methanol levels are not available in a timely manner, continue therapy until the estimated time of clearance of ethylene glycol and/or methanol has elapsed <b>and</b> the patient is asymptomatic with a normal pH. Depending upon the physical status of the patient and their endogenous metabolism of ethanol, it is important to perform frequent serum ethanol concentrations to determine the precise dose for each patient. Titrating above or below the stated doses may be necessary. If patient has coingested ethanol, measure the baseline serum ethanol concentration and adjust the ethyl alcohol loading dose based on results to achieve a serum ethanol level of ~100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">Absolute ethyl alcohol [98% (196 proof) = 77.4 g EtOH/dL]:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: Note:</b> Consider consulting with a clinical toxicologist or poison control center for options related to compounding IV ethanol.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 600 to 700 mg/kg [equivalent to 7.6 to 8.9 mL/kg using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who do <b>not </b>use alcohol regularly:</i> 66 mg/kg/hour [equivalent to 0.83 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who use alcohol regularly:</i> 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment for hemodialysis:</b> Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who do <b>not</b> use alcohol regularly:</i> 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who use alcohol regularly:</i> 257 mg/kg/hour [equivalent to 3.26 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: Note:</b> Solution must be diluted to a ≤20% concentration (to reduce the risk of gastritis) with water or juice and administered orally or via a nasogastric tube. Due to the pharmacokinetics of alcohol (ethyl) it is critical that oral ethanol be administered precisely at 60-minute intervals.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 600 to 700 mg/kg [equivalent to 0.78 to 0.9 mL/kg using a <b>98% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who do <b>not</b> use alcohol regularly:</i> 66 mg/kg/hour [equivalent to 0.09 mL/kg/hour using a <b>98% solution</b>].</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who use alcohol regularly:</i> 154 mg/kg/hour [equivalent to 0.20 mL/kg/hour using a <b>98% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment for hemodialysis:</b> Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who do <b>not</b> use alcohol regularly:</i> 169 mg/kg/hour [equivalent to 0.22 mL/kg/hour using a <b>98% solution</b>].</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients who use alcohol regularly:</i> 257 mg/kg/hour [equivalent to 0.33 mL/kg/hour using a <b>98% solution</b>]</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990513"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Methanol or ethylene glycol ingestion (off-label use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10497633','lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10497633','lexi-content-ref-12216995'])">Ref</a></span>):</b>
<i>Absolute ethyl alcohol:</i> Dosage adjustment for hemodialysis: Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who do <b>not</b> use alcohol regularly:</i> 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who use alcohol regularly:</i> 257 mg/kg/hour [equivalent to 3.26 mL/kg/hour using a <b>10% solution</b>].</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who do <b>not</b> use alcohol regularly:</i> 169 mg/kg/hour [equivalent to 0.22 mL/kg/hour using a <b>98% solution</b>].</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients who use alcohol regularly:</i> 257 mg/kg/hour [equivalent to 0.33 mL/kg/hour using a <b>98% solution</b>].</p></div>
<div class="block doha drugH1Div" id="F51844260"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F131092"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure, heart block, myocardial necrosis (excessive), ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Hyperesthesia, neuritis, pain, paresthesia</p></div>
<div class="block coi drugH1Div" id="F131102"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ethyl alcohol or any component of the formulation; seizure disorder and diabetic coma; subarachnoid injection of dehydrated alcohol in patients receiving anticoagulants</p>
<p style="text-indent:-2em;margin-left:2em;">Ablysinol: There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F131090"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>• </b>Heart block (septal ablation): Transient heart block is common at the time alcohol is injected into a septal artery; ~10% of complete heart block events become permanent and require a permanent pacemaker following percutaneous transluminal septal myocardial ablation. Risk factors for permanent pacemaker dependency include a baseline PQ interval &gt;160 msec, baseline minimum heart rate &lt;50 bpm, baseline left ventricular outflow gradient &gt;70 mmHg, maximum QRS during the first 48 hours &gt;155 msec, third-degree atrio-ventricular block occurring during the procedure, and no clinical recovery between 12 to 48 hours after the procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>• </b>Myocardial infarction: Use is intended to create a controlled MI for therapeutic purposes. However, excessive myocardial necrosis and subsequent heart failure have been reported. Factors increasing the risk of excessive tissue necrosis include higher volume of alcohol used and a higher number of septal branches injected to reduce the left ventricular outflow tract gradient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>• </b>Ventricular arrhythmia (septal ablation): Ventricular tachycardia and ventricular fibrillation requiring electrocardioversion occurred at a frequency of approximately 1%. Perform continuous electrocardiographic monitoring for 48 hours after the procedure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; ethyl alcohol may decrease blood sugar.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: Use with caution in patients with gout.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Shock: Use with caution in patients with shock.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cranial surgery: Use with caution in patients following cranial surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; the rate of heart blocks, pacemaker dependency, and dysrhythmia following injection into a septal artery increased with age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infants: Minimize dermal exposure of ethyl alcohol in infants as significant systemic absorption and toxicity can occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Parenteral: Proper positioning of the patient for neurolytic administration is essential to control localization of the injection of dehydrated alcohol (which is hypobaric) into the subarachnoid space; avoid extravasation. Not for SubQ administration. Do not administer simultaneously with blood due to the possibility of pseudoagglutination or hemolysis; may potentiate severe hypoprothrombic bleeding. Avoid extravasation during IV administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antiseptic: Appropriate use: Improper use may lead to product contamination. Although infrequent, product contamination has been associated with reports of localized and systemic infections. To reduce the risk of infection, ensure antiseptic products are used according to the labeled instructions; avoid diluting products after opening; and apply single-use containers only one time to one patient and discard any unused solution (FDA Drug Safety Communication 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Monitoring: Clinical evaluation and periodic lab determinations, including serum ethanol levels, are necessary to monitor effectiveness, changes in electrolyte concentrations, and acid-base balance (when used as an antidote). Monitor blood glucose closely, particularly in children as treatment of ingestions is associated with hypoglycemia.</p></div>
<div class="block foc drugH1Div" id="F131096"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Aerosol, foam, topical [instant hand sanitizer]:</p>
<p style="text-indent:-2em;margin-left:4em;">Epi-Clenz: 62% (240 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Foam, topical [instant hand sanitizer]:</p>
<p style="text-indent:-2em;margin-left:4em;">Purell Advanced: 70% (45 mL, 535 mL, 700 mL, 1200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, topical [instant hand sanitizer]:</p>
<p style="text-indent:-2em;margin-left:4em;">Epi-Clenz: 70% (45 mL, 120 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Epi-Clenz Plus: 62% (45 mL, 800 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">GelRite: 62% (120 mL, 480 mL, 800 mL, 1000 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Prevacare: 60% (120 mL, 240 mL, 960 mL, 1200 mL, 1500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">ProtecTeaV: 70% (236 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;">Purell: 62% (15 mL, 30 mL, 59 mL, 60 mL, 120 mL, 236 mL, 240 mL, 250 mL, 360 mL, 500 mL, 800 mL, 1000 mL, 2000 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Purell Advanced: 70% (30 mL, 236 mL, 1000 mL, 2000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [dehydrated, preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Ablysinol: ≥99% (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 98% (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid, topical [denatured]:</p>
<p style="text-indent:-2em;margin-left:4em;">Lavacol: 70% (473 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 70% (480 mL, 3840 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Pad, topical [instant hand sanitizer/towelette]:</p>
<p style="text-indent:-2em;margin-left:4em;">Purell: 62% (24s, 35s, 40s, 100s, 120s, 175s, 1000s, 4000s)</p></div>
<div class="block geq drugH1Div" id="F131086"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322968"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (CareTouch Hand Sanitizer External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75% (per mL): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Clever Choice Hand Sanitizer External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (HandClean Hand Sanitizer External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70% (per mL): $0.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Medi-First Antiseptic Cleaner External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">66.5% (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Prevacare Antimicrobial External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60% (per mL): $0.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612192"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Ethylene glycol or methanol ingestion: After diluting ethyl alcohol (98% ethanol injection solution) to ≤20% solution, administer hourly by mouth or via nasogastric tube. Out-of-hospital management with orally administered ethanol is not recommended but has been demonstrated to be efficacious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26875060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26875060'])">Ref</a></span>). Due to the pharmacokinetics of alcohol (ethyl), it is critical that oral ethanol be administered precisely at 60-minute intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Not for SubQ administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Ethylene glycol or methanol ingestion: After diluting ethyl alcohol (98% ethanol injection solution) to 10% v/v solution, infuse initial dose IV over 60 minutes; central vein is the preferred route.</p>
<p style="text-indent:-2em;margin-left:4em;">Occluded central venous catheter/central venous catheter lock: After diluting ethyl alcohol (98% ethanol injection solution) to 70% solution, instill with a volume equal to the internal volume of the catheter; assess patency at 30 to 60 minutes (or per institutional protocol); may repeat. Ensure adequate measurement of catheter volume to ensure adequate coverage of line and no excess ethanol is administered. Ethanol forms a visual precipitate with heparin or citrate, flush catheter well with normal saline before administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18029955','lexi-content-ref-20959638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18029955','lexi-content-ref-20959638'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F131099"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Ethylene glycol or methanol ingestion: Dilute ethyl alcohol to ≤20% solution (to reduce the risk of gastritis) with water or juice and administer hourly by mouth or via nasogastric tube. Out-of-hospital management with orally administered ethanol is not recommended but has been demonstrated to be efficacious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26875060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26875060'])">Ref</a></span>). Due to the pharmacokinetics of alcohol (ethyl) it is critical that oral ethanol be administered precisely at 60-minute intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Ethylene glycol or methanol ingestion (off-label use): IV administration via a central vein is the preferred route. Administer as a 10% solution in D5W. Initial dose should be administered over 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of occluded central venous catheter: Instill a 70% solution with a volume equal to the internal volume of the catheter. Assess patency at 30 to 60 minutes (or per institutional protocol).</p>
<p style="text-indent:-2em;margin-left:2em;">Intraneural: Separate needles should be used for each of multiple injections or sites to prevent residual alcohol deposition at sites not intended for tissue destruction. Inject slowly after determining proper placement of needle. Since dehydrated alcohol is hypobaric when compared with spinal fluid, proper positioning of the patient is essential to control localization of injections into the subarachnoid space.</p>
<p style="text-indent:-2em;margin-left:2em;">Intracoronary: Inject small volumes over 1 to 2 minutes percutaneously into septal arterial branches, guided by assessment of the gradient.</p></div>
<div class="block sts drugH1Div" id="F25188563"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at room temperature. Do not refrigerate or freeze. Highly flammable; store away from any heat source and keep cool.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 180 to 360 g be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53565234"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Therapeutic neurolysis of nerves or ganglia for the relief of intractable, chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (dehydrated alcohol injection) (FDA approved in adults); epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia, celiac plexus block to relieve pain of inoperable upper abdominal cancer, and intra- and subcutaneously for relief of intractable pruritus ani (diluted [40% to 50%] dehydrated alcohol injection: FDA approved in adults); has also been used as an antidote for the treatment of methanol and ethylene glycol ingestion, as a lock solution for the prevention and treatment of catheter related infections, and for treatment of occluded central venous catheters due to lipid deposition from fat emulsion infusion (particularly 3-in-1 admixture)</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Skin antiseptic (hand sanitizer gels, foams solutions and rubbing ethyl alcohol: FDA approved pediatric patients [age not specified] and adults)</p></div>
<div class="block mst drugH1Div" id="F131139"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ethanol may be confused with Ethyol, Ethamolin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298697"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Induces</b> CYP2E1 (weak)</p></div>
<div class="block dri drugH1Div" id="F6217619"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Alcohol (Ethyl) may enhance the hepatotoxic effect of Acetaminophen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetohydroxamic Acid: Alcohol (Ethyl) may enhance the adverse/toxic effect of Acetohydroxamic Acid. Specifically, Alcohol (Ethyl) may increase the risk of Acetohydroxamic Acid associated rash. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acitretin: Alcohol (Ethyl) may enhance the teratogenic effect of Acitretin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Agomelatine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: Alcohol (Ethyl) may enhance the sedative effect of Alizapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Alcohol (Ethyl) may diminish the therapeutic effect of Alpha-Lipoic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alcohol (Ethyl) may enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminophylline: Alcohol (Ethyl) may increase the serum concentration of Aminophylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apomorphine: Alcohol (Ethyl) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil: Alcohol (Ethyl) may diminish the therapeutic effect of Armodafinil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may diminish the therapeutic effect of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Systemic): Alcohol (Ethyl) may enhance the sedative effect of Azelastine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: Alcohol (Ethyl) may enhance the hepatotoxic effect of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biperiden: Alcohol (Ethyl) may enhance the adverse/toxic effect of Biperiden. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcarbonate: May interact via an unknown mechanism with Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: Alcohol (Ethyl) may enhance the CNS depressant effect of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the sedative effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: Alcohol (Ethyl) may enhance the CNS depressant effect of Brotizolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Alcohol (Ethyl) may enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment.  Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the sedative effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefamandole: Alcohol (Ethyl) may enhance the adverse/toxic effect of Cefamandole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefbuperazone: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefmetazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). Management: Consider avoiding alcohol during cefmetazole administration and for at least 1 week after therapy is completed. If alcohol is consumed during cefmetazole therapy, monitor for adverse effects such as flushing, nausea, tachycardia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefminox: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefoperazone: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CefoTEtan: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpiramide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Cefpiramide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: Alcohol (Ethyl) may enhance the CNS depressant effect of Chlormethiazole.  Management: Monitor for excessive depressant effects with this combination; caution patients about serious CNS depression if used concurrently. Chlormethiazole should not be used in persons with an alcohol use disorder who continue to consume alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Chlorphenesin Carbamate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorzoxazone: Alcohol (Ethyl) may enhance the CNS depressant effect of Chlorzoxazone. Alcohol (Ethyl) may decrease the serum concentration of Chlorzoxazone. Specifically, chronic alcohol ingestion may decrease serum concentrations of chlorzoxazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, Alcohol (Ethyl) sedative and psychomotor effects may be enhanced.  Alcohol (Ethyl) may also worsen nocturnal heartburn. Cisapride may increase the serum concentration of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: Alcohol (Ethyl) may enhance the CNS depressant effect of CloBAZam. Alcohol (Ethyl) may increase the serum concentration of CloBAZam.  Management: Patients taking clobazam should avoid alcohol consumption. If combined, patients should be informed that the CNS depressant effects of alcohol and clobazam may be potentiated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloNIDine: Alcohol (Ethyl) may enhance the CNS depressant effect of CloNIDine. Alcohol (Ethyl) may increase the serum concentration of CloNIDine. Specifically, the rate of dissolution from the clonidine extended-release tablet may be enhanced in the presence of alcohol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSERINE: Alcohol (Ethyl) may enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: Alcohol (Ethyl) may diminish the therapeutic effect of Cyproterone. More specifically, alcohol may interfere with antiandrogenic effects of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Alcohol (Ethyl) may enhance the adverse/toxic effect of Cysteamine (Systemic). Alcohol (Ethyl) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: Alcohol (Ethyl) may enhance the CNS depressant effect of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Alcohol (Ethyl) may increase the serum concentration of Deferiprone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: Alcohol (Ethyl) may decrease the serum concentration of Dexlansoprazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: Alcohol (Ethyl) may enhance the CNS depressant effect of Diamorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diethylpropion: Alcohol (Ethyl) may enhance the adverse/toxic effect of Diethylpropion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diroximel Fumarate: Alcohol (Ethyl) may decrease serum concentrations of the active metabolite(s) of Diroximel Fumarate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: Alcohol (Ethyl) may enhance the CNS depressant effect of Doxylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May enhance the adverse/toxic effect of Alcohol (Ethyl). Efavirenz may decrease the serum concentration of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Alcohol (Ethyl) may enhance the adverse/toxic effect of Eluxadoline. Specifically, alcohol use may increase the risk of pancreatitis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethionamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezogabine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ezogabine. Alcohol (Ethyl) may increase the serum concentration of Ezogabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: Alcohol (Ethyl) may enhance the CNS depressant effect of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Alcohol (Ethyl) may enhance the adverse/toxic effect of Fexinidazole. A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: Alcohol (Ethyl) may enhance the hypotensive effect of Flibanserin.  Management: Wait at least 2 hours after consuming 1 or 2 standard alcoholic drinks before taking flibanserin. Skip the flibanserin dose if 3 or more alcoholic drinks were consumed that evening. After taking flibanserin at bedtime, do not drink until the next day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: Alcohol (Ethyl) may enhance the CNS depressant effect of Flunitrazepam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin-Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin Enacarbil: Alcohol (Ethyl) may enhance the CNS depressant effect of Gabapentin Enacarbil. Alcohol (Ethyl) may increase the absorption of Gabapentin Enacarbil. Specifically, the rate of absorption may be enhanced, as alcohol may speed the release of drug from the extended-release tablet. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: Alcohol (Ethyl) may enhance the CNS depressant effect of GuanFACINE. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: Alcohol (Ethyl) may enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodone.  Management: Patients using hydrocodone extended-release capsules must not consume alcohol or alcohol-containing products due to possibly fatal outcomes. Other hydrocodone products are also expected to interact, but to a less significant degree.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: Alcohol (Ethyl) may enhance the sedative effect of Indoramin. Alcohol (Ethyl) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Alcohol (Ethyl) may enhance the hepatotoxic effect of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ISOtretinoin (Systemic): Alcohol (Ethyl) may enhance the adverse/toxic effect of ISOtretinoin (Systemic). Specifically, the risk for elevated triglyceride concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). Management: Advise patients to avoid alcohol ingestion while taking ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: Alcohol (Ethyl) may enhance the CNS depressant effect of Lemborexant. Alcohol (Ethyl) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: Alcohol (Ethyl) may enhance the vasodilatory effect of Lercanidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Alcohol (Ethyl) may enhance the adverse/toxic effect of Levoketoconazole. Specifically, a disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Alcohol (Ethyl) may enhance the adverse/toxic effect of Levomethadone. Specifically, the risk for sedation, respiratory depression, coma, and death may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: Alcohol (Ethyl) may increase the absorption of Levomilnacipran. More specifically, Alcohol (Ethyl) may cause more rapid release of Levomilnacipran from extended-release tablets, which could accelerate absorption early post-dose. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Alcohol (Ethyl) may enhance the CNS depressant effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Alcohol (Ethyl) may enhance the hepatotoxic effect of Lomitapide.  Management: Advise patients to limit alcohol consumption to 1 drink per day while receiving lomitapide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LORazepam: Alcohol (Ethyl) may enhance the CNS depressant effect of LORazepam. Alcohol (Ethyl) may increase the serum concentration of LORazepam. Specifically, this increase in concentration would only occur with use of lorazepam extended release capsules and alcohol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: Alcohol (Ethyl) may enhance the CNS depressant effect of Lormetazepam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Melatonin. Alcohol (Ethyl) may diminish the therapeutic effect of Melatonin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Alcohol (Ethyl) may enhance the CNS depressant effect of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Alcohol (Ethyl) may enhance the adverse/toxic effect of MetFORMIN. Specifically, excessive alcohol ingestion (acute or chronic) may potentiate the risk of lactic acidosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Alcohol (Ethyl) may enhance the hepatotoxic effect of Methotrexate.  Management: Limit alcohol consumption in patients taking methotrexate. The use of methotrexate for the treatment of psoriasis or rheumatoid arthritis is contraindicated in patients with alcoholism or alcoholic liver disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, CNS depressant effects may be increased.  Management: Avoid alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Alcohol (Ethyl) may enhance the CNS depressant effect of Methoxyflurane. Alcohol (Ethyl) may increase the metabolism of Methoxyflurane. Specifically, this increased metabolism may lead to increased production of nephrotoxic metabolites. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. Management: Warn patients and monitor for signs and symptoms of a disulfiram-like reaction if patients consume alcohol while using topical metronidazole. Some manufacturers of vaginal metronidazole products list alcohol use within 24 to 72 hours as a contraindication<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Alcohol (Ethyl) may enhance the hepatotoxic effect of Mipomersen.  Management: Patients being treated with mipomersen should limit their consumption of alcohol to a maximum of 1 drink (or equivalent) per day. With any concurrent use, patients should be followed more closely for evidence of hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: Alcohol (Ethyl) may enhance the CNS depressant effect of Mirtazapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Modafinil: Alcohol (Ethyl) may diminish the therapeutic effect of Modafinil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morniflumate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Morniflumate. Specifically, consumption of more than 3 alcoholic drinks per day may increase the risk of gastrointestinal hemorrhage during Morniflumate treatment. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefopam: Alcohol (Ethyl) may enhance the CNS depressant effect of Nefopam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Niacin.  Management: Avoid alcohol around the time of niacin administration to minimize flushing. Use caution in patients who drink larger amounts of alcohol due to the potential for enhanced hepatotoxicity. Consider monitoring serum transaminases more frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niclosamide: May increase the absorption of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Alcohol (Ethyl) may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: Alcohol (Ethyl) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nifurtimox: Alcohol (Ethyl) may enhance the adverse/toxic effect of Nifurtimox. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilutamide: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, nilutamide may increase the likelihood of alcohol intolerance (eg, facial flushing, malaise, hypotension).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Alcohol (Ethyl) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): Alcohol (Ethyl) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Topical). Specifically, the risk of GI bleeding may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Normethadone: Alcohol (Ethyl) may enhance the adverse/toxic effect of Normethadone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: Alcohol (Ethyl) may diminish the therapeutic effect of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir.  Management: Avoid alcohol consumption within 4 hours of taking the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product. This interaction does not apply to the immediate-release ombitasvir/paritaprevir/ritonavir/dasabuvir product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: Alcohol (Ethyl) may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: Alcohol (Ethyl) may enhance the CNS depressant effect of OXcarbazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Alcohol (Ethyl) may enhance the CNS depressant effect of Oxybate Salt Products. Alcohol (Ethyl) may increase the serum concentration of Oxybate Salt Products. Specifically, alcohol may increase concentrations of the sodium oxybate extended release suspension. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyBUTYnin: Alcohol (Ethyl) may enhance the CNS depressant effect of OxyBUTYnin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of Alcohol (Ethyl). Alcohol may also worsen the negative behavioral and psychiatric effects of Perampanel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phendimetrazine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Phendimetrazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pheniramine: Alcohol (Ethyl) may enhance the CNS depressant effect of Pheniramine.  Management: Caution patients to avoid the use of alcohol together with pheniramine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phentermine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Phentermine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Alcohol (Ethyl) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Alcohol (Ethyl) may enhance the dermatologic adverse effect of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, sedative and psychomotor effects may be enhanced.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Alcohol (Ethyl) may enhance the sedative effect of Piribedil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Alcohol (Ethyl) may increase the serum concentration of Posaconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: Alcohol (Ethyl) may enhance the hepatotoxic effect of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Alcohol (Ethyl) may enhance the hepatotoxic effect of Propacetamol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: Alcohol (Ethyl) may decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Prothionamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: Alcohol (Ethyl) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Rilmenidine. Specifically, alcohol increased the CNS depressant effect of rilmenidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Rufinamide. Specifically, sleepiness and dizziness may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Alcohol (Ethyl) may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.  Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran.  Management: Consider advising patients to avoid concomitant use of alcohol with SNRIs, particularly those using extended-release SNRI formulations, due to the risk of accelerated drug release. Heavy alcohol use has been associated with overdose and hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: May enhance the sedative effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: May enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Alcohol (Ethyl) may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulthiame: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, concurrent use may result in a disulfiram-like reaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: Alcohol (Ethyl) may enhance the CNS depressant effect of Suvorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Alcohol (Ethyl) may increase the absorption of Tacrolimus (Systemic). More specifically, the initial absorption rate may be increased, as alcohol may speed the release of tacrolimus from extended-release tablets.  Management: Advise patients receiving extended-release tacrolimus (Astagraf XL or Envarsus XR brands) not to take the medication with alcoholic beverages.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Alcohol (Ethyl) may enhance the dermatologic adverse effect of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tapentadol: Alcohol (Ethyl) may enhance the CNS depressant effect of Tapentadol. Alcohol (Ethyl) may increase the serum concentration of Tapentadol. Specifically, alcohol may increase the maximum serum concentrations when used with extended-release tapentadol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline: Alcohol (Ethyl) may increase the serum concentration of Theophylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Alcohol (Ethyl) may enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tinidazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiopronin: Alcohol (Ethyl) may increase the bioavailability of Tiopronin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Alcohol (Ethyl) may enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval.  Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: Alcohol (Ethyl) may enhance the hepatotoxic effect of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: Alcohol (Ethyl) may enhance the adverse/toxic effect of TraZODone. Specifically, effects on sleepiness, dizziness, and manual dexterity may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethobenzamide: Alcohol (Ethyl) may enhance the CNS depressant effect of Trimethobenzamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trospium: Alcohol (Ethyl) may enhance the CNS depressant effect of Trospium.  Management: Avoid consuming any alcohol within 2 hours of taking a dose of trospium XR. Alcohol may increase sedation and CNS depressant effects of trospium XR.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Alcohol (Ethyl) may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varenicline (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may be decreased and the risk for neuropsychiatric adverse effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasodilators (Organic Nitrates): Alcohol (Ethyl) may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Alcohol (Ethyl) may decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months).  The role of alcohol itself is unclear. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: Alcohol (Ethyl) may enhance the adverse/toxic effect of Zopiclone. Specifically, taking alcohol with zopiclone may increase the risk of complex sleep-related behaviors (eg, sleep-driving, eating food, making phone calls, leaving the house, etc.) Alcohol (Ethyl) may enhance the CNS depressant effect of Zopiclone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54119811"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Since a "safe" amount of ethanol consumption during pregnancy has not been determined, the AAP recommends women who are planning a pregnancy refrain from all ethanol intake (AAP 2000).</p></div>
<div class="block pri drugH1Div" id="F131105"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ethanol crosses the placenta, enters the fetal circulation, and has teratogenic effects in humans (AAP 2000; Barceloux 1999).</p>
<p style="text-indent:0em;margin-top:2em;">The following withdrawal symptoms have been noted in the neonate following maternal ethanol consumption during pregnancy: Crying, hyperactivity, irritability, poor suck, tremors, seizures, poor sleeping pattern, hyperphagia, and diaphoresis (Hudak 2012). Fetal alcohol syndrome (FAS) is a term referring to a combination of physical, behavioral, and cognitive abnormalities resulting from ethanol exposure during fetal development. Since a "safe" amount of ethanol consumption during pregnancy has not been determined, the AAP recommends those women who are pregnant refrain from all ethanol intake (AAP 2000).</p>
<p style="text-indent:0em;margin-top:2em;">When used as an antidote during the second or third trimester, FAS is not likely to occur due to the short treatment period; use during the first trimester is controversial (Barceloux 1999). Following administration into a septal artery during percutaneous transluminal septal myocardial ablation, systemic concentrations are not expected to result in significant exposure of ethanol to the fetus, however the procedure should be postponed until after delivery when possible.</p></div>
<div class="block mopp drugH1Div" id="F53565235"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">
<b>Ethylene glycol or methanol ingestion:</b> Blood ethanol levels (at the end of the loading dose, every 1 to 2 hours until stabilized, and then every 2 to 4 hours thereafter); blood glucose, electrolytes (including serum magnesium), arterial pH, blood gases, methanol or ethylene glycol blood levels, heart rate, blood pressure.</p></div>
<div class="block rerp drugH1Div" id="F53565222"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Symptoms associated with serum ethanol levels:</p>
<p style="text-indent:-2em;margin-left:4em;">Nausea and vomiting: Serum level &gt;100 mg/dL (SI: &gt;21.7 mmol/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Coma: Serum level &gt;300 mg/dL (SI: &gt;65.1 mmol/L)</p>
<p style="text-indent:-2em;margin-left:2em;">Antidote for methanol/ethylene glycol: Goal range: Blood ethanol level: 100 to 150 mg/dL (SI: 21.7 to 32.6 mmol/L)</p></div>
<div class="block pha drugH1Div" id="F131089"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ethylene glycol or methanol overdose (off-label use):</b> Ethyl alcohol competitively inhibits alcohol dehydrogenase (AD), an enzyme that catalyzes the metabolism of ethylene glycol and methanol to their toxic metabolites. AD has a higher affinity for ethanol; therefore, ethanol is preferentially metabolized in patients who have ingested ethylene glycol and/or methanol. As a result, treatment with ethanol prevents the formation of ethylene glycol and methanol toxic metabolites, thereby preventing the development of toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurolysis:</b> Alcohol will destroy nerves at the site of injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Septal ablation:</b> Tissue toxin that produces a myocardial infarction when injected through an intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.</p></div>
<div class="block phk drugH1Div" id="F131101"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.6 to 0.7 L/kg; decreased in women</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (90% to 98%) to acetaldehyde or acetate</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Rate: 15 to 20 mg/dL/hour (range: 10 to 34 mg/dL/hour); increased in patients with alcohol use disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Kidneys and lungs (~2% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F131107"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">By derm alcohol | Dg 6 alcohol | Germikill | Merthiolate alcohol | Sanitizante</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alcohol dehydrated | Bactol alcohol gel | Microshield antimicrobial</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alcool</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Akuel | Alcohol etilico | Alcohol gel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fugaten | Septoman</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Manitas limpias</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aniosgel 85 npc | Chemisept fg</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alcowipes | Levermed | Primahex | Primasol | Purell</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Quicklean</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Naksol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Handy clean</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Chemisept fg | Naksol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aniosgel 85 npc | Chemisept fg | Chemisept vir+ | Naksol | Septivon Handgel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aniosgel 85 npc | Septi gel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Microshield</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alcohol dehydrated | Dehydrated alcohol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aniosgel 85 npc</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Naksol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alcohol dehydrated | Joycare alcohol swab</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alcohol | Quicklean</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Curethyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bio Seeds | Disinfection | Hand sanitizer</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Ablysinol.1">
<a name="Ablysinol.1"></a>Ablysinol (dehydrated alcohol) [prescribing information]. Largo, FL: Belcher Pharmaceuticals; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10920168">
<a name="10920168"></a>American Academy of Pediatrics (AAP). Committee on Substance Abuse and Committee on Children With Disabilities, Fetal Alcohol Syndrome and Alcohol-Related Neurodevelopmental Disorders. <i>Pediatrics.</i> 2000;106(2):358-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/10920168/pubmed" id="10920168" target="_blank">10920168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10497633">
<a name="10497633"></a>Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. <i>J Toxicol Clin Toxicol.</i> 1999;37(5):537-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/10497633/pubmed" id="10497633" target="_blank">10497633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12216995">
<a name="12216995"></a>Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning. Ad Hoc Committee. <i>J Toxicol Clin Toxicol.</i> 2002;40(4):415-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/12216995/pubmed" id="12216995" target="_blank">12216995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21844829">
<a name="21844829"></a>Blackwood RA, Klein KC, Micel LN, et al. Ethanol locks therapy for resolution of fungal catheter infections. <i>Pediatr Infect Dis J</i>. 2011;30(12):1105-1107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21844829/pubmed" id="21844829" target="_blank">21844829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16235508">
<a name="16235508"></a>Caravati EM, Erdman AR, Christianson G, et al. Ethylene Glycol Exposure: An Evidence-Based Consensus Guideline for Out-of-Hospital Management. <i>Clin Toxicol (Phila).</i> 2005;43(5):327-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/16235508/pubmed" id="16235508" target="_blank">16235508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18029955">
<a name="18029955"></a>Cober MP, Johnson CE. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. <i>Am J Health Syst Pharm</i>. 2007;64(23):2480-2482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/18029955/pubmed" id="18029955" target="_blank">18029955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20959638">
<a name="20959638"></a>Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. <i>JPEN J Parenter Enteral Nutr</i>. 2011;35(1):67-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/20959638/pubmed" id="20959638" target="_blank">20959638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12902914">
<a name="12902914"></a>Dannenberg C, Bierbach U, Rothe A, Beer J, Körholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. <i>J Pediatr Hematol Oncol</i>. 2003;25(8):616-621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/12902914/pubmed" id="12902914" target="_blank">12902914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care.<i> Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valesco.1">
<a name="Valesco.1"></a>Dehydrated alcohol [prescribing information]. Elkhorn, NE: Valesco Pharmaceuticals LLC; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration. FDA Drug Safety Communication: FDA requests label changes and single-use packaging for some over-the-counter topical antiseptic products to decrease risk of infection. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm374711.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm374711.htm</a>. Updated November 20, 2013. Accessed October 1, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal [published correction appears in <i>Pediatrics</i>. 2014;133(5):937]. <i>Pediatrics</i>. 2012;129(2):e540-e560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20620333">
<a name="20620333"></a>Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure.<i> J Pediatr Surg</i>. 2010;45(6):1287-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/20620333/pubmed" id="20620333" target="_blank">20620333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11852608">
<a name="11852608"></a>Koren G. Drinking Alcohol While Breastfeeding. Will it Harm My Baby? <i>Can Fam Physician.</i> 2002;48(5):39-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/11852608/pubmed" id="11852608" target="_blank">11852608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18639955">
<a name="18639955"></a>Lepik KJ, Levy AR, Sobolev BG, et al. Adverse Drug Events Associated With the Antidotes for Methanol and Ethylene Glycol Poisoning: A Comparison of Ethanol and Fomepizole. <i>Ann Emerg Med.</i> 2009;53(4):439-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/18639955/pubmed" id="18639955" target="_blank">18639955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lepik.1">
<a name="Lepik.1"></a>Lepik KJ, Sobolev BG, Levy AR, et al. Medication Errors Associated With the Use of Ethanol and Fomepizole as Antidotes for Methanol and Ethylene Glycol Poisoning. <i>Clin Toxicol (Phila).</i> 2011;49(5):391-401.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14607462">
<a name="14607462"></a>Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. <i>J Am Coll Cardiol.</i> 2003;42(9):1687-1713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/14607462/pubmed" id="14607462" target="_blank">14607462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21622689">
<a name="21622689"></a>McGrath EJ, Salloum R, Chen X, et al. Short-dwell ethanol lock therapy in children is associated with increased clearance of central line-associated bloodstream infections. <i>Clin Pediatr (Phila)</i>. 2011;50(10):943-951.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21622689/pubmed" id="21622689" target="_blank">21622689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. <i>Chest.</i> 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18558177">
<a name="18558177"></a>Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. <i>J Pediatr Surg</i>. 2008;43(6):1025-1029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/18558177/pubmed" id="18558177" target="_blank">18558177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21460264">
<a name="21460264"></a>O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. <i>Clin Infect Dis</i>. 2011;52(9):e162-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21460264/pubmed" id="21460264" target="_blank">21460264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17018464">
<a name="17018464"></a>Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. <i>Arch Pediatr Adolesc Med</i>. 2006;160(10):1049-1053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/17018464/pubmed" id="17018464" target="_blank">17018464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3116300">
<a name="3116300"></a>Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion.<i> JPEN J Parenter Enteral Nutr</i>. 1987;11(5):507-508l.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/3116300/pubmed" id="3116300" target="_blank">3116300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23232749">
<a name="23232749"></a>Pieroni KP, Nespor C, Ng M, et al. Evaluation of ethanol lock therapy in pediatric patients on long-term parenteral nutrition. <i>Nutr Clin Pract</i>. 2013;28(2):226-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23232749/pubmed" id="23232749" target="_blank">23232749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23045557">
<a name="23045557"></a>Ralls MW, Blackwood RA, Arnold MA, Partipilo ML, Dimond J, Teitelbaum DH. Drug shortage-associated increase in catheter-related blood stream infection in children. <i>Pediatrics</i>. 2012;130(5):e1369-1373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23045557/pubmed" id="23045557" target="_blank">23045557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25836677">
<a name="25836677"></a>Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. <i>Breastfeed Med</i>. 2015;10(3):135-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/25836677/pubmed" id="25836677" target="_blank">25836677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9462563">
<a name="9462563"></a>Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 Patients. <i>J Am Coll Cardiol.</i> 1998;31(2):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/9462563/pubmed" id="9462563" target="_blank">9462563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23076968">
<a name="23076968"></a>Sorajja P, Ommen SR, Holmes DR Jr, et al. Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. <i>Circulation. </i>2012;126(20):2374-2380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23076968/pubmed" id="23076968" target="_blank">23076968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21499184">
<a name="21499184"></a>Valentine KM. Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit.<i> Pediatr Crit Care Med</i>. 2011;12(6):e292-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21499184/pubmed" id="21499184" target="_blank">21499184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21616259">
<a name="21616259"></a>Wales PW, Kosar C, Carricato M, de Silva N, Lang K, Avitzur Y. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience.<i> J Pediatr Surg</i>. 2011;46(5):951-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21616259/pubmed" id="21616259" target="_blank">21616259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8577023">
<a name="8577023"></a>Werlin SL, Lausten T, Jessens, et al. Treatment of Central Venous Catheter Occlusions With Ethanol and Hydrochloric Acid. <i>JPEN J Parenter Enteral Nutr.</i> 1995;19(5):416-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/8577023/pubmed" id="8577023" target="_blank">8577023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25732977">
<a name="25732977"></a>Zakharov S, Navratil T, Salek T, Kurcova I, Pelclova D. Fluctuations in serum ethanol concentration in the treatment of acute methanol poisoning: a prospective study of 21 patients. <i>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</i>. 2015;159(4):666-676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/25732977/pubmed" id="25732977" target="_blank">25732977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26109326">
<a name="26109326"></a>Zakharov S, Pelclova D, Navratil T, et al. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. <i>Clin Toxicol (Phila)</i>. 2015;53(8):797-806. doi:10.3109/15563650.2015.1059946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/26109326/pubmed" id="26109326" target="_blank">26109326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26875060">
<a name="26875060"></a>Zakharov S, Pelclova D, Urban P, et al. Use of out-of-hospital ethanol administration to improve outcome in mass methanol outbreaks. <i>Ann Emerg Med</i>. 2016;68(1):52-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/26875060/pubmed" id="26875060" target="_blank">26875060</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13289 Version 284.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
